Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis
Humanistic burden and health-related quality of life
15 evidence topics · 14 sources
SF-36 component scores, anxiety, and depression in 136 US adults with physician-diagnosed NASH versus matched general population and type 2 diabetes cohorts, 2016 National Health and Wellness Survey
“Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States. Respondents with physician-diagnosed NASH, physician-diagnosed T2DM, and respondents from the general population were compared.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NASH cohort did not differ from matched T2DM cohort (N = 272) on mental or work-related WPAI scores, but had significantly worse physical status (PCS 40.52 vs. 44.58, p = 0.001), higher % with anxiety (39.9% vs 27.8%, p = 0.043)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network
“QOL data were collected from adults with NAFLD enrolled in the NASH Clinical Research Network using the SF-36 survey and scores were compared to normative U.S. population scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 713 subjects with NAFLD (M=269, F=444) were included. Mean age of subjects was 48.3 years; 61% had definite NASH, and 28% had bridging fibrosis or cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects with NAFLD had worse physical (mean=45.2) and mental health scores (mean=47.6) compared to the U.S. population with (mean=50) and without (physical: 55.8, mental: 52.5) chronic illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects with cirrhosis had significantly (P<0.001) poorer physical health scores (38.4) vs. subjects with no (47.6), mild (46.2), moderate (44.6) or bridging fibrosis (44.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mental health scores did not differ between participants with and without NASH or by degree of fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical health-related patient-reported outcomes in 72 adults with biopsy-proven NASH and F2 or F3 fibrosis, as summarized in a systematic review
“Biopsy-proven NASH with stage F2/F3 fibrosis (72)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, physical health-related PROs of patients with NASH were lower than established general population levels, regardless of fibrosis stage (F3: p <0.05 for physical functioning, role-physical, general health, and PCS of SF-36; F2: p <0.05 for general health and PCS of SF-36)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Health-related work productivity and activity impairment scores at baseline were significantly greater than 0 (p <0.05 except for absenteeism)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes in 1667 adults with NASH and F3 or F4 fibrosis versus the general population, STELLAR trial baseline
“We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline
“were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446
“Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH
“There were 4,213 MASH patients included: age 56 ± 11 years, 44% male, 65% type 2 diabetes, 69% advanced fibrosis (F3–F4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After item reduction and exploratory factor analysis with the training set (>90% variance), the CLDQ-MASH contained 35 items and seven domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, in the context of liver disease severity, the CLDQ-MASH was able to discriminate individuals with vs. without histologic advanced fibrosis (p <0.05 for three domains and the total score)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CLDQ-NAFLD disease-specific instrument: 36 items in six domains
“Thus, the resulting Chronic Liver Disease Questionnaire-Non-Alcoholic Fatty Liver Disease version instrument had 36 items grouped into six domains: Abdominal Symptoms, Activity, Emotional, Fatigue, Systemic Symptoms, and Worry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The domains' correlations with the most relevant domains of Short Form-36 exceeded 0.70.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study
“The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire – Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average CLDQ-NAFLD index was 4.9, with France having the highest score at 5.7 and the USA having the lowest score of 4.4 (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Index and population, mean (SD) | Early (F0–F2) | Advanced (F3–F4) | Overall |
|---|---|---|---|
| EQ-5D index, United States (n = 58, 36, 94) | “0.80 (0.19)”View highlighted excerpt for this quote | “0.67 (0.23)”View highlighted excerpt for this quote | “0.75 (0.22)”View highlighted excerpt for this quote |
| EQ-5D index, all countries (n = 531, 218, 749) | “0.80 (0.2)”View highlighted excerpt for this quote | “0.62 (0.33)”View highlighted excerpt for this quote | “0.75 (0.26)”View highlighted excerpt for this quote |
| CLDQ-NAFLD index, USA (n = 55, 36, 91) | “4.7 (1.05)”View highlighted excerpt for this quote | “4.0 (1.12)”View highlighted excerpt for this quote | “4.4 (1.12)”View highlighted excerpt for this quote |
| CLDQ-NAFLD index, all countries (n = 513, 210, 723) | “5.2 (1.1)”View highlighted excerpt for this quote | “4.4 (1.4)”View highlighted excerpt for this quote | “4.9 (1.2)”View highlighted excerpt for this quote |
EQ-5D-5L by fibrosis stage and cardiovascular, renal, and metabolic comorbidity in adults with MASH, Canada, France, Germany, and Italy, 2024
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean EQ-5D-5L scores were lower for EFwC patients (0.85 ± 0.16 [n = 524]) and AFwC patients (0.81 ± 0.18 [n = 113]) compared with EFnoC patients (0.90 ± 0.12 [n = 48], p <0.05 and p <0.001, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with AFwC experienced greater cognitive and emotional impairment, required professional caregivers more often, and had increased rates of hospitalization compared with those with EFwC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1
“Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo plus standard of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 800 participants were included in this analysis (semaglutide 2.4 mg n = 534; placebo n = 266).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“31.3% of participants had stage 2 fibrosis, 68.8% had stage 3 fibrosis, and 55.9% had type 2 diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across the study population, the baseline mapped health utility (∼0.78, Table 1) was lower than that reported in the literature for a similar patient population (0.84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Baseline group | Baseline EQ-5D utility, mean (SD) |
|---|---|
| Fibrosis stage 2, semaglutide (n = 169) | “0.783 (0.186)”View highlighted excerpt for this quote |
| Fibrosis stage 2, placebo (n = 81) | “0.789 (0.190)”View highlighted excerpt for this quote |
| Fibrosis stage 3, semaglutide (n = 365) | “0.792 (0.176)”View highlighted excerpt for this quote |
| Fibrosis stage 3, placebo (n = 185) | “0.769 (0.194)”View highlighted excerpt for this quote |
Pruritus, fatigue, and sleep disorders in 8034 adults with MASLD, Global NAFLD/MASLD Registry
“Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SF-6D health utility in noncirrhotic and cirrhotic NAFLD, 89 outpatients
“There were 89 patients with the spectrum of NAFLD completed the SF-36 questionnaire: 59 with non-cirrhotic NAFLD and 30 with cirrhosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD had significantly lower quality of life and health utility scores than the general population (all p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic NAFLD patients: SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life in NASH: systematic review of 23 studies
“Twenty-five publications covering 23 unique studies were identified. Overall, the data showed a substantial impact of NASH on HRQoL, particularly in terms of physical functioning and fatigue, with deterioration of physical and mental health as NASH progresses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalent symptoms, including fatigue, abdominal pain, anxiety/depression, cognition problems, and poor sleep quality, adversely impact patients’ ability to work and perform activities of daily living and the quality of relationships.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most studies were rated ‘moderate’ at quality assessment, and all evaluable studies had inadequate control of confounders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis stage and quality of life: meta-analysis of 13 cohort studies
“Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three studies examined the effects of increasing fibrosis on quality of life had inconsistent findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further studies are needed to assess the association between fibrosis stage and patient quality of life and establish that change in liver fibrosis stage is a valid endpoint for use in clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote